Foundation Medicine Inc (FMI) CFO Jason Ryan Sells 15,000 Shares of Stock

Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $67.53, for a total value of $1,012,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jason Ryan also recently made the following trade(s):

  • On Tuesday, January 16th, Jason Ryan sold 21,035 shares of Foundation Medicine stock. The shares were sold at an average price of $64.38, for a total value of $1,354,233.30.
  • On Tuesday, January 2nd, Jason Ryan sold 2,336 shares of Foundation Medicine stock. The shares were sold at an average price of $64.00, for a total value of $149,504.00.
  • On Tuesday, December 5th, Jason Ryan sold 21,726 shares of Foundation Medicine stock. The shares were sold at an average price of $61.26, for a total value of $1,330,934.76.

Foundation Medicine Inc (NASDAQ:FMI) opened at $76.60 on Wednesday. Foundation Medicine Inc has a 52-week low of $22.40 and a 52-week high of $78.00. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. The firm has a market capitalization of $2,780.00, a P/E ratio of -17.14 and a beta of -0.03.

A number of hedge funds have recently bought and sold shares of FMI. Lord Abbett & CO. LLC increased its position in Foundation Medicine by 146.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after buying an additional 343,770 shares in the last quarter. Peregrine Capital Management LLC bought a new position in Foundation Medicine during the 3rd quarter valued at approximately $13,299,000. State Street Corp increased its position in Foundation Medicine by 124.2% during the 2nd quarter. State Street Corp now owns 526,775 shares of the company’s stock valued at $20,947,000 after buying an additional 291,815 shares in the last quarter. Boston Advisors LLC bought a new position in Foundation Medicine during the 4th quarter valued at approximately $13,000,000. Finally, Advisory Research Inc. increased its position in Foundation Medicine by 172.2% during the 4th quarter. Advisory Research Inc. now owns 76,581 shares of the company’s stock valued at $5,223,000 after buying an additional 48,450 shares in the last quarter. 30.86% of the stock is owned by institutional investors.

A number of research analysts have recently commented on the company. Cowen assumed coverage on Foundation Medicine in a research note on Thursday, February 15th. They issued an “outperform” rating and a $90.00 target price for the company. BidaskClub cut Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Saturday, February 10th. Zacks Investment Research raised Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Thursday, February 8th. Finally, Goldman Sachs Group started coverage on Foundation Medicine in a research report on Monday, January 29th. They set a “neutral” rating and a $73.00 price objective for the company. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Foundation Medicine currently has a consensus rating of “Hold” and a consensus target price of $59.80.

WARNING: “Foundation Medicine Inc (FMI) CFO Jason Ryan Sells 15,000 Shares of Stock” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/21/foundation-medicine-inc-fmi-cfo-jason-ryan-sells-15000-shares-of-stock.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply